Clinical Cancer Research Versailles No Abst Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 2601, May 1, 2008. doi: 10.1158/1078-0432.CCR-07-5026
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, X.-J.
Right arrow Articles by Sgroi, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, X.-J.
Right arrow Articles by Sgroi, D.

Imaging, Diagnosis, Prognosis

A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer

Xiao-Jun Ma1, Ranelle Salunga1, Sonika Dahiya2, Wilson Wang1, Erin Carney2, Virginie Durbecq4, Adrian Harris5, Paul Goss3, Christos Sotiriou4, Mark Erlander1 and Dennis Sgroi2

Authors' Affiliations: 1 AviaraDx, Inc., San Diego, California; 2 Department of Pathology, Harvard Medical School, Molecular Pathology Research Unit, Massachusetts General Hospital and 3 Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts; 4 Translational Research Unit, Jules Bordet Institute, Brussels, Belgium; and 5 John Radcliffe Hospital, Oxford, United Kingdom

Requests for reprints: Dennis Sgroi, Department of Pathology, Harvard Medical School, Molecular Pathology Research Unit, Massachusetts General Hospital, Boston, MA 02129. Phone: 617-726-5697; Fax: 617-726-5697; E-mail: dsgroi{at}partners.org or Mark Erlander, 11025 Roselle St., Suite 200, San Diego, CA 92121. E-mail: merlander{at}aviaradx.com.

Purpose: Histologic tumor grade is a well-established prognostic factor for breast cancer, and tumor grade–associated genes are the common denominator of many prognostic gene signatures. The objectives of this study are as follows: (a) to develop a simple gene expression index for tumor grade (molecular grade index or MGI), and (b) to determine whether MGI and our previously described HOXB13:IL17BR index together provide improved prognostic information.

Experimental Design: From our previously published list of genes whose expression correlates with both tumor grade and tumor stage progression, we selected five cell cycle–related genes to build MGI and evaluated MGI in two publicly available microarray data sets totaling 410 patients. Using two additional cohorts (n = 323), we developed a real-time reverse transcription PCR assay for MGI, validated its prognostic utility, and examined its interaction with HOXB13:IL17BR.

Results: MGI performed consistently as a strong prognostic factor and was comparable with a more complex 97-gene genomic grade index in multiple data sets. In patients treated with endocrine therapy, MGI and HOXB13:IL17BR modified each other's prognostic performance. High MGI was associated with significantly worse outcome only in combination with high HOXB13:IL17BR, and likewise, high HOXB13:IL17BR was significantly associated with poor outcome only in combination with high MGI.

Conclusions: We developed and validated a five-gene reverse transcription PCR assay for MGI suitable for analyzing routine formalin-fixed paraffin-embedded clinical samples. The combination of MGI and HOXB13:IL17BR outperforms either alone and identifies a subgroup (~30%) of early stage estrogen receptor–positive breast cancer patients with very poor outcome despite endocrine therapy.




This article has been cited by other articles:


Home page
NEJMHome page
C. Sotiriou and L. Pusztai
Gene-Expression Signatures in Breast Cancer
N. Engl. J. Med., February 19, 2009; 360(8): 790 - 800.
[Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S Badve and H Nakshatri
Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications
J. Clin. Pathol., January 1, 2009; 62(1): 6 - 12.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Dowsett and A. K. Dunbier
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
Clin. Cancer Res., December 15, 2008; 14(24): 8019 - 8026.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Desmedt, B. Haibe-Kains, P. Wirapati, M. Buyse, D. Larsimont, G. Bontempi, M. Delorenzi, M. Piccart, and C. Sotiriou
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Clin. Cancer Res., August 15, 2008; 14(16): 5158 - 5165.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.